KIM FOREST (6645) reported revenue of NT$83.2 million for Oct 2026, +40.3% year on year and -0.5% from the previous month. Revenue for Jan–Oct 2026 was NT$578 million (+33.9% year on year).
Year-on-year revenue growth: 6 months in a row. →
In Oct 2026, it ranked No. 84 by revenue among 160 Biotech & Medical companies.
Monthly revenue chart
Hover over (or tap) a bar to see that month’s revenue.
Monthly revenue history
| Month | Revenue | YoY | MoM |
|---|---|---|---|
| Oct 2026 | NT$83.2 million | +40.3% | -0.5% |
| Sep 2026 | NT$83.6 million | +103.5% | +20.1% |
| Aug 2026 | NT$69.6 million | +27.0% | +10.3% |
| Jul 2026 | NT$63.1 million | +30.4% | -4.4% |
| Jun 2026 | NT$66.1 million | +43.9% | +22.4% |
| May 2026 | NT$54 million | +40.1% | +55.3% |
| Apr 2026 | NT$34.8 million | -15.5% | -18.4% |
| Mar 2026 | NT$42.6 million | +14.9% | +18.8% |
| Feb 2026 | NT$35.9 million | +12.0% | -20.5% |
| Jan 2026 | NT$45.1 million | +35.8% | -26.7% |
| Dec 2025 | NT$61.6 million | +1.5% | +10.0% |
| Nov 2025 | NT$56 million | +9.5% | -5.6% |
| Oct 2025 | NT$59.3 million | +24.8% | +44.3% |
| Sep 2025 | NT$41.1 million | -11.5% | -25.0% |
| Aug 2025 | NT$54.8 million | +30.6% | +13.3% |
| Jul 2025 | NT$48.4 million | +34.1% | +5.5% |
| Jun 2025 | NT$45.9 million | -7.2% | +19.2% |
| May 2025 | NT$38.5 million | -4.0% | -6.4% |
| Apr 2025 | NT$41.1 million | +29.9% | +10.9% |
| Mar 2025 | NT$37.1 million | +2.0% | +15.8% |
| Feb 2025 | NT$32 million | +6.1% | -3.7% |
| Jan 2025 | NT$33.2 million | +11.2% | -45.2% |
| Dec 2024 | NT$60.7 million | +17.2% | +18.6% |
| Nov 2024 | NT$51.1 million | +3.2% | +7.6% |
| Oct 2024 | NT$47.5 million | +94.6% | +2.3% |
Jan–Oct 2026 cumulative: NT$578 million (+33.9% YoY)
Other Biotech & Medical companies
Compare with peers: KIM FOREST vs PEC / KIM FOREST vs Lotus Pharm / KIM FOREST vs Bora
| Company | Revenue | YoY |
|---|---|---|
| PEC | NT$2.84 billion | +102.0% |
| Lotus Pharm | NT$2.13 billion | -22.5% |
| Bora | NT$1.99 billion | +15.9% |
| Great Tree Pharmacy | NT$1.67 billion | +1.5% |
| EXCELSIOR | NT$1.02 billion | +38.6% |
| PEGAVISION | NT$793 million | +13.0% |
| Synmosa Biopharma | NT$766.6 million | +41.2% |
| Y.S.H. | NT$749.4 million | +4.4% |
See also
← All Taiwan listed & OTC companies
Sources: Taiwan Stock Exchange, monthly revenue of listed companies (Government Open Data Platform); Taipei Exchange, monthly revenue of OTC companies (TPEx OpenAPI); historical months from MOPS. Amounts in New Taiwan dollars. Changes calculated by this site from the source figures. Not investment advice. Updated: 2026-11-16